This issue of JCP Visuals is available in Adobe Acrobat Portable Document Format (PDF). For a description of PDF and Adobe Acrobat Reader, please visit our Online Media Page.

Download the Posttest CME or CE credit (if you prefer not to take the Posttest online for instant credit)

To obtain credit, please study the activity material and complete the posttest as instructed.

CME Objectives

After completing this educational activity, participants should be able to:

Define functional impairment related to ADHD in home, school, social, and self domains
Use nonpharmacologic and pharmacologic treatments for functional impairments in ADHD

CE Objectives

Describe the physical symptoms of ADHD
Discuss the goal of therapy in terms of relief of functional impairments

Statement of Need and Purpose

Attention-deficit/hyperactivity disorder (ADHD) affects the domains of the home, the social, the school, and the self. ADHD, which is one of the most frequently diagnosed disorders in children and often persists into adolescence and adulthood, is associated with a variety of functional impairments that lead to poor social, educational, and occupational outcomes. This activity was designed to meet the needs of participants in CME activities provided by Physicians Postgraduate Press, Inc. who have requested information on functional outcomes in children and adolescents with ADHD. There are no prerequisites for participating in this activity.

Accreditation Statement

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Mississippi Bureau of Pharmaceutical Services is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Credit Designation

Physicians Postgraduate Press, Inc. designates this educational activity for up to 1 Category 1 credit* toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity.

*CME credit cannot be given for both JCP Visuals and PCC Visuals posttests.

Date of Original Release/Review

This JCP Visuals was published in July 2003. This activity is eligible for CME credit through July 31, 2005 and for CE credit through July 31, 2004. The latest review of this material was June 2003.

This Program (#032-999-03-055-H01) is approved for 1 hour (0.1 CEU) of continuing pharmaceutical education credit.

Faculty

Rakesh Jain, M.D., M.P.H., Chair
Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, and Director of Psychopharmacology Research, R/D Clinical Research, Inc., Lake Jackson, Tex.

David A. Duesenberg, M.D.
Mercy Health Research and St. Louis University School of Medicine, Mo.

Craig L. Donnelly, M.D.
Department of Psychiatry, Dartmouth Medical School, Lebanon, N.H.

Faculty Disclosure

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this continuing medical education activity were asked to complete a full disclosure statement. The information received is as follows:

Dr. Jain is a consultant for Eli Lilly and GlaxoSmithKline; has received grant/research support from Wyeth, GlaxoSmithKline, Eli Lilly, and Merck; has received honoraria from Wyeth, GlaxoSmithKline, and Eli Lilly; and is a member of the speakers/advisory board for Eli Lilly.

Dr. Duesenberg is a consultant for and has received honoraria from Eli Lilly and Shire Richwood; has received grant/research support from Eli Lilly, Shire Richwood, Novartis, and Johnson & Johnson; and is a member of the speakers/advisory boards for Eli Lilly, Shire Richwood, and Forest.

Dr. Donnelly is an employee of Dartmouth Medical School; is a consultant for Eli Lilly and Pfizer; has received grant/research support from Janssen, Pfizer, and Eli Lilly; has received honoraria from GlaxoSmithKline and AstraZeneca; and is a member of the speakers/advisory boards for Eli Lilly, Pfizer, Janssen, and GlaxoSmithKline.

Disclosure of Off-Label Usage

To the best of his knowledge, Dr. Jain has determined that bupropion, clonidine, desipramine, guanfacine, and imipramine are not approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Acknowledgment

This JCP Visuals was derived from the teleconference "Functional Outcomes in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder" held April 29, 2003, and was independently developed by the Physicians Postgraduate Press, Inc. Office of Continuing Medical Education pursuant to an unrestricted educational grant from Eli Lilly and Company. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.